Doximity, Inc. (DOCS) Spending and interest coverage
- R&D / revenue · 12 months: Value 21.72%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 20.82%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 21.72% | Research and development expense / revenue. Period ending 2026-06-30. $142.38M ÷ $655.57M × 100 ≈ 21.72% |
| Stock-based compensation / revenue · 12 months | 20.82% | Share-based compensation / revenue. Period ending 2026-06-30. $136.51M ÷ $655.57M × 100 ≈ 20.82% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 142.38M USD | Research and Development Expense |
| Revenue | 655.57M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 136.51M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 194.05M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $142.38M | $655.57M | $136.51M | $194.05M | (m) | 21.72% | 20.82% | (m) | (m) |
| 2026-03-31 | $130.70M | $644.86M | $121.63M | $214.92M | (m) | 20.27% | 18.86% | (m) | (m) |
| 2025-12-31 | $116.40M | $637.78M | $102.94M | $238.77M | (m) | 18.25% | 16.14% | (m) | (m) |
| 2025-09-30 | $104.22M | $621.33M | $88.77M | $246.80M | (m) | 16.77% | 14.29% | (m) | (m) |
| 2025-06-30 | $97.26M | $589.64M | $77.16M | $236.26M | (m) | 16.50% | 13.09% | (m) | (m) |
| 2025-03-31 | $93.04M | $570.40M | $72.39M | $227.80M | (m) | 16.31% | 12.69% | (m) | (m) |
| 2024-12-31 | $88.38M | $550.17M | $66.18M | $220.97M | (m) | 16.06% | 12.03% | (m) | (m) |
| 2024-09-30 | $85.91M | $516.85M | $58.59M | $199.60M | (m) | 16.62% | 11.34% | (m) | (m) |
| 2024-06-30 | $82.63M | $493.63M | $54.16M | $180.25M | (m) | 16.74% | 10.97% | (m) | (m) |
| 2024-03-31 | $81.98M | $475.42M | $51.08M | $163.88M | (m) | 17.24% | 10.74% | (m) | (m) |
| 2023-12-31 | $83.38M | $468.33M | $52.21M | $154.87M | (m) | 17.80% | 11.15% | (m) | (m) |
| 2023-09-30 | $83.95M | $448.31M | $54.42M | $134.80M | (m) | 18.73% | 12.14% | (m) | (m) |
| 2023-06-30 | $83.09M | $436.88M | $52.33M | $133.11M | (m) | 19.02% | 11.98% | (m) | (m) |
| 2023-03-31 | $80.19M | $419.05M | $47.83M | $125.11M | (m) | 19.14% | 11.41% | (m) | (m) |
| 2022-12-31 | $76.07M | $401.74M | $44.65M | $120.19M | (m) | 18.93% | 11.11% | (m) | (m) |
| 2022-09-30 | $71.78M | $384.35M | $40.50M | $117.49M | (m) | 18.67% | 10.54% | (m) | (m) |
| 2022-06-30 | $68.13M | $361.52M | $35.82M | $110.34M | (m) | 18.85% | 9.91% | (m) | (m) |
| 2022-03-31 | $62.35M | $343.55M | $31.44M | $113.54M | (m) | 18.15% | 9.15% | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $43.87M | $206.90M | $7.25M | $53.30M | (m) | 21.21% | 3.51% | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $32.44M | $116.39M | $2.35M | $22.16M | (m) | 27.87% | 2.02% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.